登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H11N5
化学文摘社编号:
分子量:
285.30
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
来曲唑, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
SMILES string
N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3
InChI key
HPJKCIUCZWXJDR-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
letrozole
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... CYP19A1(1588)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
来曲唑是一种非甾体芳香酶抑制剂。
来曲唑是第三代非甾体芳香酶抑制剂。 它是芳香酶系统的竞争性抑制剂，因此可抑制雄激素向雌激素转化。来曲唑通过竞争性结合到该酶的细胞色素P450亚基的血红素上而抑制芳香酶，导致所有组织中雌激素的生物合成减少。
Application
Letrozole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2 - STOT RE 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
监管及禁止进口产品
此项目有
Pamela J Goodwin et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(21), 2231-2239 (2014-06-18)
Obesity is associated with poor outcomes in women with operable breast cancer. Lifestyle interventions (LIs) that help women reduce their weight may improve outcomes. We conducted a multicenter randomized trial comparing mail-based delivery of general health information alone or combined
G Allevi et al.
British journal of cancer, 108(8), 1587-1592 (2013-04-13)
The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response. This single institution
Valentina Guarneri et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(10), 1050-1057 (2014-03-05)
This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) -positive/human epidermal growth factor receptor 2 (HER2) -negative operable breast cancer. Ninety-two
Antonio C Wolff et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(2), 195-202 (2012-12-13)
Recent data showed improvement in progression-free survival (PFS) when adding everolimus to exemestane in patients with advanced breast cancer experiencing recurrence/progression after nonsteroidal aromatase inhibitor (AI) therapy. Here, we report clinical outcomes of combining the mammalian target of rapamycin (mTOR)
Volkan Turan et al.
Fertility and sterility, 100(6), 1681-1685 (2013-09-24)
To investigate the safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole protocol for fertility preservation in breast cancer patients. Retrospective cohort study. Academic fertility preservation center. Seventy-eight women ≤ 45 years, diagnosed with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持